Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs N-acetylcysteine-amide (Primary)
- Indications Cystinosis; Retinitis pigmentosa; Usher syndromes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SLO RP
- Sponsors Nacuity Pharmaceuticals
- 14 Nov 2024 Planned End Date changed from 1 May 2025 to 1 Aug 2025.
- 14 Nov 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Jun 2025.
- 07 Feb 2024 Planned End Date changed from 1 Jan 2025 to 1 May 2025.